

AKR7L Blocking Peptide (N-Term)
Synthetic peptide
Catalog # BP21497a**Specification**

AKR7L Blocking Peptide (N-Term) - Product InformationPrimary Accession [Q8NHP1](#)**AKR7L Blocking Peptide (N-Term) - Additional Information****Gene ID** 246181**Other Names**

Aflatoxin B1 aldehyde reductase member 4, 1---, AFB1 aldehyde reductase 3, AFB1-AR 3, Aldoketoreductase 7-like, AKR7L, AFAR3, AKR7A4

Target/Specificity

The synthetic peptide sequence is selected from aa 32-44 of HUMAN AKR7L

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

AKR7L Blocking Peptide (N-Term) - Protein Information**Name** AKR7L**Synonyms** AFAR3 {ECO:0000303|PubMed:12879023}, AKR**Function**

Can reduce the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the non-binding AFB1 dialcohol. May be involved in protection of liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen (By similarity).

Tissue Location

Mainly expressed in uterus.

AKR7L Blocking Peptide (N-Term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

AKR7L Blocking Peptide (N-Term) - Images

AKR7L Blocking Peptide (N-Term) - Background

Can reduce the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the non-binding AFB1 dialcohol. May be involved in protection of liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen (By similarity).

AKR7L Blocking Peptide (N-Term) - References

Gregory S.G.,et al.Nature 441:315-321(2006).
Praml C.,et al.Oncogene 22:4765-4773(2003).